Société des Produits Nestlé SA engages in the manufacture and distribution of food, pharmaceutical, medical, and cosmetic products. The company was founded on December 15, 1936 and is headquartered in Vevey, France.

Daicel Corp. engages in the manufacture and sale of chemical products. It operates through the following segments: Cellulosic Derivatives, Organic Chemicals, Plastics, Pyrotechnic Devices, and Others. The Cellulosic Derivatives segment engages in the production of various cellulosic derivatives such as cellulose acetate, acetate tow for cigarette filters, and water-soluble polymers. The Organic Chemicals segment offers various solvents and fine chemicals; acetic acid, and chiral columns used for separation of optical isomers. The Plastic segment develops unique products for numerous industrial sectors such as engineering plastics, polymer alloys and cyclic-olefin copolymers; and also develops a variety of plastic processed products such as polystyrene sheets, formed trays, and functional films. The Pyrotechnic Devices segment provides motor vehicle safety devices, airbag inflators, aerospace and defense systems. The Others segment includes membrane and warehousing business. The company was founded on September 8, 1919 and is headquartered in Osaka, Japan.

Nestec SA, a subsidiary of Nestlé SA, is a Swiss company located in Vevey. The firm manufactures nutrition food products.

RaQualia began operations in July 2008 with a corporate mission, "They seek to bring people health and happiness through innovative new medications." Thanks to the support of all of their stakeholders, the company was listed on the JASDAQ Growth Market in July 2011. They have transformed RaQualia's R&D strategy, which is now based on the concept of "selection and concentration." They are now focusing on their core competencies in targeting ion channels in the fields of pain and gastrointestinal disease. In addition, they have made a strategic decision to relocate RaQualia's discovery processes to Nagoya University to better promote synergy effects with academia. With the Chubu region as their base, they are continuing with further efforts enhance their capabilities in drug discovery, improve shareholder value, and achieve financial stability by promoting licensing activities and alliance management with their corporate partners. They will continue to work tirelessly in providing patients with innovative medicines sooner by increasing the pace of drug development. Thank you very much for your continued support of RaQualia.

Daiwa Can Co. Ltd. manufactures and markets metal cans and plastic containers for food, cosmetic, and beverage products. The company was founded in 1939 and is headquartered in Tokyo, Japan.

The Nisshin OilliO Group, Ltd. engages in the manufacture, processing, and distribution of edible oils. It operates through the following segments: Oils and Fats, Modified Fats, Fine Chemicals, Healthy Food and Others. The Oils and Fats segment manufactures and supplies edible oil products for home use, commercial purpose, and food processing. The Modified Fats segment manufactures and supplies modified fats and chocolates. The Fine Chemicals segment manufactures and supplies cosmetic raw materials and chemical substances. The Healthy Food segment manufactures and supplies dressings and mayonnaise. The Others segment deals with temporary staffing, insurance agency, and golf driving range and equipment rental businesses. The company was founded by Kihachiro Okura and Kyujiro Matsushita on February 22, 1907 and is headquartered in Tokyo, Japan.

Time For Medicine Ltd. provides specialist diagnoses and treatments using cloud technology. The firm specializes in dermatology, allergy, integrated sexual health and remote diagnosis. The company was founded by Clive Minihan and Paul Williams in 2009 and is headquartered in London, the United Kingdom.

Part of Danone SA, Nutricia NV is a Dutch company located in Zoetermeer that manufactures dry, condensed and evaporated dairy products.

Bayer AG engages in the development, manufacture and distribution of products in the areas of health care, nutrition and high-tech materials. It operates through the following segments: Pharmaceuticals, Consumer Health, Crop Science, Animal Health and Covestro. The Pharmaceuticals segment engages in the development, production and marketing of prescription products for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology and ophthalmology; diagnostic imaging equipment and the necessary contrast agents. The Consumer Health segment manufactures and markets products in the dermatology, dietary supplement, analgesic, gastrointestinal, cold, allergy, sinus and flu, foot care and sun protection categories. The CropScience segment includes seeds and plant traits, crop protection and nonagricultural pest control. The Animal Health segment offers prescription and nonprescription veterinary products. The Covestro segment provides raw materials for polyurethanes; polycarbonate granules and sheets; raw materials for coatings, adhesives and sealants; and by-products of polyether production and of chlorine production and use. The company was founded by Friedrich Bayer and Johann Friedrich Westkott on August 1, 1863 and is headquartered in Leverkusen, Germany.

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core segment. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli, and Brett P. Monia in 1989 and is headquartered in Carlsbad, CA.

Guangxi Dongxing Mountain Dendrobium Co., Ltd., established on 2011-09-29, Business scope includes dendrobium cultivation,roughing,research and development,Acquisition and sale;poultry,livestock farming,Sales;vegetable,fruit,seedlings,trees,Planting and sales of flowers;stay,Catering Services;Primary processing service of agricultural products,Sales;food production,processing,buy and sell;Research and development of agricultural science and technology,to promote,Transfer and Application;Import and export,Technology import and export business.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments.)

Established in 1973 in Korea, Hanmi Pharmaceuticals now is one of the top 5 pharmaceutical companies in terms of revenue, and the most R&D focused company with the highest R&D investment for several years. Hanmi has been successful for a few decades with high flexibility, continuously changing its market/development strategy from first generics to IMD & FDC (Incrementally Modified Drug and Fixed Dose Combination) to new drug development including innovative small molecules and biologics. During the period of significant changes, Hanmi made multiple strategic collaboration relationships with multinational companies and biotech companies. Based on the success in 1980s and 1990s, Hanmi started its Chinese operation in 1996 with establishment of Beijing Hanmi. Now, Beijing Hanmi grew as a well-localized and well-settled Chinese company with more than 1,300 staffs including R&D, sales / marketing, and manufacturing experts and significant growth rate higher than 20% every year. Currently, Hanmi and Beijing Hanmi is closely collaborating on various business opportunities and new drug development projects as well as sales and marketing in Chinese territories. As the only Asian company with significant presence both in Korea and China, as the most R&D focused company with number of clinical stage projects with competitiveness, and as the company with open innovation based on multiple development/marketing collaborations, Hanmi is trying to develop and provide differentiated treatment options to patients suffering from various disease.

Etypharm is a French private company, also operating in FR. The firm provides healthcare services.

Pfizer Inc. (NYSE: PFE, /ˈfaɪzər/) is an American multinational pharmaceutical corporation headquartered in New York City was founded in 1849, based in New York City and was listed on New York Stock Exchange. It is one of the world's largest pharmaceutical companies. It is listed on the New York Stock Exchange, and its shares have been a component of the Dow Jones Industrial Average since 2004. Pfizer ranked No. 57 on the 2018 Fortune 500 list of the largest United States corporations by total revenue.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Ajinomoto Co. is a global manufacturer of high-quality seasonings, processed foods, beverages, amino acids, pharmaceuticals and specialty chemicals. For many decades Ajinomoto Co. has contributed to food culture and human health through wide-ranging application of amino acid technologies. Today, the company is becoming increasingly involved with solutions for improved food resources, human health and global sustainability. Founded in 1909 and now operating in 26 countries, Ajinomoto Co. had net sales of JPY 1,197.3 billion (USD 15.1 billion) in fiscal 2011. The Ajinomoto Group Standards of Business Conduct (hereinafter the "Standards of Conduct") describe the conduct that every member of the Ajinomoto Group must understand and practice every day in order to implement the Ajinomoto Group Philosophy in accordance with the Ajinomoto Group Way. The Standards of Conduct also represent the commitments made to all stakeholders by Ajinomoto Group companies. Ajinomoto aim to be "a group of companies that contributes to human health globally" by continually creating unique value to benefit customers. To become a global group of food companies centered on the world's No. 1 seasoning business. To become a global group of aminoscience companies that contributes to humankind with the world's No. 1 amino acid technology. To become a group of health-promoting companies with a scientific approach to good taste and health.